Datapoint: Actemra Scores Systemic Sclerosis Nod

The FDA last week cleared Genentech’s Actemra for the treatment of systemic sclerosis, a rare autoimmune disease occurring in patients with interstitial lung disease. The drug is the first biologic approved for this condition, and will be Actemra’s sixth FDA-granted indication overall. For the treatment of rheumatoid arthritis, Actemra currently holds preferred status for 21% of all covered lives under the pharmacy benefit, with utilization management restrictions applied in most cases. The biologic is classified as a specialty drug for 14% of covered lives.

SOURCE: MMIT Analytics, as of 3/8/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 23

Datapoint: HealthPartners to Launch Insurance Products With Avera

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 19

Datapoint: Lilly Scores Diabetes, Obesity Nods for Mounjaro

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 18

Datapoint: CDPHP Selects New PBM

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today